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Abstract
The transcription factor zinc finger E-box binding protein 2 (ZEB2) controls embryonic and adult cell fate decisions and
cellular maturation in many stem/progenitor cell types. Defects in these processes in specific cell types underlie several
aspects of Mowat–Wilson syndrome (MOWS), which is caused by ZEB2 haplo-insufficiency. Human ZEB2, like mouse Zeb2, is
located on chromosome 2 downstream of a ±3.5 Mb-long gene-desert, lacking any protein-coding gene. Using temporal
targeted chromatin capture (T2C), we show major chromatin structural changes based on mapping in-cis proximities
between the ZEB2 promoter and this gene desert during neural differentiation of human-induced pluripotent stem cells,
including at early neuroprogenitor cell (NPC)/rosette state, where ZEB2 mRNA levels increase significantly. Combining T2C
with histone-3 acetylation mapping, we identified three novel candidate enhancers about 500 kb upstream of the ZEB2
transcription start site. Functional luciferase-based assays in heterologous cells and NPCs reveal co-operation between these
three enhancers. This study is the first to document in-cis Regulatory Elements located in ZEB2’s gene desert. The results
further show the usability of T2C for future studies of ZEB2 REs in differentiation and maturation of multiple cell types and
the molecular characterization of newly identified MOWS patients that lack mutations in ZEB2 protein-coding exons.
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Introduction
Genome-wide identification of regulatory elements (REs), using
the mapping of epigenetic modifications and transcription fac-
tor (TF) binding sites coupled to chromatin conformation cap-
ture analyses at different resolutions (3C and beyond), strongly
indicate the occurrence of DNA looping between promoters
and distal enhancers in controlling cell fate and differentia-
tion. These transcriptionally functional DNA loops occur within
large interaction-domains, the so-called topologically associat-
ing domains (TADs), which themselves are genome-structural
loops connected by linker regions (1–5). The intra-TAD DNA
loops formed by in-cis promoter-RE proximities lead to pre-
cise cell type/stage-specific regulation of gene expression (6–9).
REs are often evolutionary highly conserved and usually flank
genes shown to control development and cell differentiation,
but also metabolic pathways (10). For example, in pluripotent
stem cells (PSCs), structural ‘hubs’ can be observed wherein the
core pluripotency factors Sox2, Nanog and Oct4 control genes
involved in the maintenance of pluripotency (e.g. Tcf3, Smarcad1)
(11). In these PSCs, the transcriptionally inactive regions are
less organized, but these regions becomemore organized during
differentiation to somatic cell types (11). It is also generally
accepted that reprogramming of somatic cells, based on trans-
duction of Oct4, Sox2, Klf4 and c-Myc (OSKM) expressable cDNA,
results in an almost complete reorganization of the genome
architecture, which then becomes similar to that of PSCs.
Zinc finger E-box binding protein 2 (Zeb2) is a TF critical
for vertebrate embryogenesis, including the development of the
central nervous system (CNS) and peripheral nervous system
(PNS) (12,13). In differentiating mouse embryonic stem cells,
Zeb2 is needed for the exit from primed pluripotency and
general as well as neural differentiation (14). In oligodendrocyte
precursor cells during embryonic CNSmyelinogenesis and adult
Schwann Cell function in PNS (re)myelination, Zeb2 plays a
dual transcriptional regulatory role, i.e. directly repressing genes
involved in inhibition of differentiation,while directly activating
(other) genes promoting cell differentiation and maturation.
In doing so, Zeb2 generates the necessary anti-bone morpho-
genetic protein (BMP)(-Smad) and anti-Wnt, and in the PNS
also the anti-Notch and anti-Sox2 activities needed for normal
progression of commitment, differentiation and maturation
in this glial cell lineage (15–18). In humans, ZEB2 haplo-
insufficiency causes the rare Mowat–Wilson syndrome (MOWS,
OMIM #235730). Patients exhibit severe intellectual disability,
epilepsy and/or seizures, Hirschsprung disease, and other
anomalies including typical craniofacial defects (19–21).Analysis
of the spectrum of the de novo mutant ZEB2 alleles in a more
recent cohort of 87 patients indicated for the first time that the
severity of MOWS may correlate with the type of mutation (21).
De novo deletions in the ZEB2 gene that involve protein-coding
exons or cause protein C-terminal truncation due to mutation
into a stop codon, aswell as even larger genomic deletions, cause
severe defects, whereas the few known missense mutations
(1.5% of about 320 exon-sequenced MOWS patients thus far)
present with a milder form of the syndrome (21,22).
Additional work done in mouse models, including rescu-
ing conventional or conditional Zeb2−/− knockout backgrounds
via introduction of a Zeb2 cDNA (provided as heterozygous or
homozygous transgene), strongly suggests that proper control
of Zeb2 amounts, including via steady-state mRNA levels, is
critical for normal Zeb2 functions, as observed from the graded
phenotypic severities of the Zeb2 knockout and/or transgene
combinations (23–26). In this respect, little is however known
about the precise and temporal transcriptional control of ZEB2,
and only few studies have thus far focused on candidate TFs that
bind to the ZEB2 proximal promoter (27,28). Recently, different
enhancers were identified,mainly by documenting evolutionary
conserved ZEB2 containing and flanking regions, followed by
validation in zebrafish, rodent models and/or in vitro cellular
models. In addition, in a transgenic rat model, Zeb2 is regulated
in a tissue- and time-specific manner by an enhancer located
1.2 Mb upstream of the transcription start site (TSS) (29). In
the subpallium of the developing mouse brain, two enhancers
flanking the Zeb2 locus have been proposed to be activated by
the TF Dlx2 (30). More recently, combining publicly available
databases of chromatin interaction and mapped histone signa-
tures, again followed by validation in zebrafish, eight enhancers
were identified in intergenic, intronic and exonic sequences of
ZEB2 (31). These enhancers are active in mid-/hindbrain regions,
trigeminal ganglia, notochord or the whole brain (31).
Human ZEB2 is located on chr2:145141942–145277958
(genome release GRCh37/hg19), downstream of a 3.3 Mb-long
region lacking protein-coding sequences, which encodes several
non-coding RNAs. The sequence of this region is locally highly
conserved between different species, despite the differences in
length of this region (chimp: 3.4 Mb; mouse: 3.7 Mb; chicken:
1 Mb; Xenopus: 1 Mb). This gene desert is located between ZEB2
and ACVR2A, which encodes for the Activin type-IIA receptor,
a component of the transforming growth factor type beta
(TGFβ)/BMP signaling system (32). In a separate study, a map of
non-coding elements involved in human cortical neurogenesis
was obtained by combining chromatin accessibility and mRNA
profiling data (33). Several non-protein coding elements are in
proximity of ZEB2, including the long non-coding RNA (lncRNA)
LINC01412, which maps roughly 2 kb upstream of the ZEB2 TSS.
In a genome-wide association study of more than 2400 cases of
aortic valve stenosis (a pathology that hits about 5% of MOWS
patients), this region harbors single-nucleotide polymorphisms
in the non-coding RNA TEX41, located about 150 kb upstream
of the ZEB2 TSS, that directly interact with LINC01412 and the
ZEB2 proximal promoter region (21,34). A schematic overview
of the ZEB2 locus, with published enhancers and chromatin
interactions that co-regulate ZEB2, is depicted in Supplementary
Material, Figure S1.
Altogether, and also considering its listing as a super-
enhancer top-gene (35,36), the gene desert upstream of the
human ZEB2 becomes a priority for identifying candidate and/or
pathologic ZEB2 REs. Given the critical role of Zeb2 during
exit from primed pluripotency, its dynamic regulation during
neural and general differentiation of mouse embryonic stem
cells, and applied rescues in knockout stem cells with inserted
Zeb2 expressible cDNA (14), we decided to study chromatin
conformation dynamics of the human ZEB2 locus during neural
differentiation of induced PSCs (iPSCs).
Several chromosome conformation capture techniques (3C,
4C, 5C, Hi-C, ChIA-PET) have been developed to investigate and
characterize spatial genomic organization by chromatin inter-
actions (37–41). These techniques are mostly expensive, require
extensive primer design and have a resolution of tens of kb.
Recently, targeted chromatin capture (T2C) was shown to virtu-
ally provide high resolution (in the order of few kb or even <1 kb)
and combine thiswith high coverage and low sequencing efforts,
hence at a contained cost (42). We therefore aimed to study
the chromatin dynamics of the ZEB2 locus, during iPSC neural
differentiation, considering the whole gene desert and both its
flanking regions, for a total genomic region of 7.4 Mb in length
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(coordinates chr2: 143270465–150642631; GRCh37/hg19 genome
reference). SupplementaryMaterial, Figure S1B shows this region
of interest used in this T2C study.
By correlating chromatin architecture reconstruction via
T2C at an average resolution below 1 kb with H3K27ac
marks, RNA-profiling at selected time points of cellular neural
differentiation, and further taking into consideration locus
sequence conservation in vertebrates, we identified three
novel candidate ZEB2 enhancers. Our work demonstrates, for
the first time, the dynamic regulation of ZEB2 expression
by distal REs that loop to the ZEB2 promoter during cell
differentiation. These studies are expected to open the road
to improved and/or expanded genetic and additional func-
tional characterization of those MOWS patients for whom no
mutation affecting the protein-encoding sequence of ZEB2 can
be identified.
Results
Transcriptomic profile of neural differentiating human
iPSCs
RNA-sequencing of undifferentiated cells (D0), early neuropro-
genitor cells (NPCs)/neural rosettes (D6) and late NPCs (D15)
was carried out (Fig. 1A; see also Materials and Methods). Prin-
cipal component analysis shows the clustering of the samples
based mainly on the time point of differentiation (PC1, Fig. 1B).
ZEB2 mRNA, as well as the transcripts of the second ZEB-family
member ZEB1, is upregulated already at D6 of differentiation
(Fig. 1C; Supplementary Material, Fig. S2A). The acknowledged
ZEB1/2 direct target gene CDH1, encoding for the epithelial cell
specific homotypic cell-cell adhesion protein E-cadherin, was
concomitantly downregulated already at D6 (Fig. 1; Supplemen-
tary Material, Fig. S2A). Its expression inversely correlated in the
bulk cell cultures with that of the N-cadherin encoding gene
CDH2 (Fig. 1C; Supplementary Material, Fig. S2A).
Expression of genes encoding the core components of the
pluripotency network, such as NANOG, POU5F1 (OCT4), SOX2,
and ZFP42 (REX1), is downregulated upon differentiation (Fig. 1C;
Supplementary Material, Fig. S2B). SOX2 is however also critical
to neurogenesis, and its expression—even though decreased
during differentiation—remains high when compared to other
pluripotency genes (43) (Supplementary Material, Fig. S2B). Con-
versely, the expression of neuroectodermmarker genes, such as
GBX2, PAX6, SIX1 and SOX1 increased (Fig. 1C; Supplementary
Material, Fig. S2C). Expression of mesendodermal genes EOMES,
GATA4, SOX17 and TBXT (T, BRACHYURY) was in this cell culture
protocol not significant (Supplementary Material, Fig. S2D). Of
the mesendodermal markers, only EOMES is upregulated at D6
and D15 compared to D0, most likely due to its proposed role in
neurodevelopment (44,45). We have also performed staining for
pluripotency marker proteins OCT4 and SOX2, for NPC markers
NESTIN, TUJ1, PAX6 and NCAM, and for ZEB2, at the considered
time points of differentiation (Fig. 1D). Taken together, the neural
differentiation protocol of the initial human iPSCs was highly
efficient.
Chromatin dynamics of ZEB2 locus during neural
differentiation
We studied the regulation of the ZEB2 locus by temporal T2C
using the iPSC system at times documented above. First, we
calculated the average size and density distribution of the frag-
ments generated by ApoI cut in the considered area. Density
distribution and frequency of the fragment size plots show a
mean fragment size (dashed line in each panel of Supplementary
Material, Fig. S3A) of ∼500 bp ApoI, which did not change during
differentiation. Reconstruction of high-resolution T2C maps at
the different time points, plotting the single fragments obtained
from the digestion with ApoI, resulted in a very sparse and
unclear figure (data not shown).Therefore,we opted for reducing
the resolution of our T2C maps by binning the signals to a
resolution of 20 kb, resulting in an easier graphical interpretation
(Fig. 2). On the other hand, theApoI fragment resolution becomes
very useful when zooming in on relatively small regions such
as these shown in Supplementary Material, Fig. S4, depicting
the ApoI fragment proximity interactions on the ZEB2 gene per
se (chr2:145141942–145277958, hg19) (see also Supplementary
Material, File S1).
As shown in Figure 2, undifferentiated iPSCs revealed a dif-
fuse pattern of proximity interactionswith few appreciable TADs
downstream of ZEB2, as well as along the gene desert and
around the ACVR2A locus. At D6 (early NPCs), the TADs became
more pronounced, with a long ∼4 Mb TAD (chr2:143–147 Mb)
being strongly defined and encompassing at least three sub-
TADs. One, which we define as TAD1 (Figs 2 and 3B), bridged
ZEB2 to ARHGAP15; another (named TAD2) did so between ZEB2
and a region located upstream its TSS in the gene desert (i.e.
around chr2:146 Mb) (Figs 2 and 3C); and one (TAD3) between
chr2:146 and chr2:147 Mb (Figs 2 and 3D). The major chromatin
conformation change observed at D6was concomitant with high
ZEB2 mRNA in early NPCs, while the less pronounced TADs at
undifferentiated state were associated with low ZEB2 expression
(Figs 1 and 2). At D15 (NPCs), the 4-Mb TAD seemed less defined,
whereas the three sub-TADswere still defined, even though their
proximity signals were reduced, suggesting a slight loosening of
the chromatin architecture (Fig. 2).
We also propose that several other TADs relate to the other
genes, which are located in the same broad chromosomal region
(KYNU, ARHGAP15, GTDC1, ACVR2A, ORC4, MBD5, EPC2, KIF5C,
LYPD6B, and MMADHC) (Fig. 2). We therefore checked in our
RNA-seq data whether transcription of these genes correlated
with the formation of these TADs in the gene desert. In gen-
eral, expression of these genes did not change during neural
differentiation (Supplementary Material, Fig. S5A).
The sub-TAD TAD1 (chr2:144–145) bridges ZEB2 with
ARHGAP15, which encodes for a Rho-GTPase-activating protein,
and is known to direct expression in both excitatory and
inhibitory neurons of the adult hippocampus and midbrain
(46,47) (Human Protein Atlas; https://www.proteinatlas.org)
(Fig. 2). ARHGAP15 mRNA expression was slightly upregulated
at D6 in our RNA-seq data (Supplementary Material, Fig. S5A).
Figure 3B and C show that ZEB2 sequences are not only in
proximity with ARHGAP15, but also that, at D6, ZEB2 bridged
with the 5′-region of GTDC1. According to the Human Protein
Atlas database, the highest levels of GTDC1 are observed in
the cerebral cortex (47).
Figure 3A and C, and Supplementary Material, Figure S4,
also clearly show a local DNA looping of the ZEB2 gene itself,
which formed at D6 and then disappeared at D15, supporting
therefore the results from Bar-Yaacov and co-workers (31)
who identified ZEB2 intragenic enhancers. ACVR2A, which
flanks the gene desert, did not show a significant change in
expression, even though TADs were forming and involved its
coding sequence (Fig. 2A). ACVR2A is highly expressed in skin
and skeletal muscle rather than brain regions, where it does
not show any significant regional expression (47) (the Human
Protein Atlas).
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Figure 1. Gene expression profiling of differentiating iPSCs. (A) Schematic overview of the differentiation protocol used, including specific media and inhibitors
(see Materials and Methods). Abbreviations used: EB, embryoid body; NIM, neural induction medium; D (day) 0, undifferentiated state; D6, early NPC/neural rosette
formation; D15, NPCs; w/o vit A, no vitamin A added to B27. (B) Principal component analysis plot showing clustering of biological repeat (n=3) RNA-seq samples
based on time of differentiation. (C) log2Fold Change heatmap of selected marker genes confirming progression from pluripotency to efficient neural differentiation.
(D) Immunofluorescence staining at selected timepoints of differentiation for pluripotency (OCT4, SOX2) and NPC markers (NCAM, NESTIN, TUJ1 and PAX6) and ZEB2.
Scale bar = 100 μm.
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Figure 2. ZEB2 locus dynamics during neural differentiation. Reconstruction of in-cis proximity interactions on the human chr2:143:151 region, including the ZEB2 locus
and the other annotated genes, in pluripotent (top panel, D0) and neural differentiating (D6, D15) iPSCs. To improve graphical clarity, the signals were binned to get a
resolution of 20 kb.
T2C mapping and H3K27Ac marks identify three novel
candidate enhancers for ZEB2
When zooming-in at D6 on the sub-TAD TAD2, formed by ZEB2
and chr2:146, we noticed long-range proximity defining a sub-
TAD that bridges ∼chr2:145260000 (ZEB2) to ∼chr2:145780000
(upstream gene desert) (blue arrow in Fig. 3C; Supplementary
Material, File S2). The coordinates for the mapped proximity
are chr2:145260000–145280000 (region A) and chr2:145760000–
145780000 (region B). In the hg19 release, region A corresponds
to the first 20 kb of ZEB2, including the promoter and (the non-
coding) exon1 and (protein-encoding) exon2, while region B
is located in an intron of the lncRNA TEX41, in the upstream
gene desert (Fig. 3C and E). Another strong interaction signal
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Figure 3. The main 143–147 Mb TAD defined at D6 is composed of three sub-TADs. At D6 (A), the major chromatin conformation encompassing the ZEB2 locus and
upstream region is evident, displayingmore intragenic proximity interactions and also threewell-defined TADs located betweenARHGAP15 and ZEB2 (TAD1,B), between
145 and 146 Mb (TAD2, C) and a third one located in the ZEB2 upstream gene desert between 146 and 147 Mb. At D6, the strongest signal is observed in a TAD structure
defined by region coordinates 145260000–145280000 to 145760000–145780000 (D). Zooming-in on the coordinates chr2:145760000–145780000 allows the definition of
three possible well conserved enhancers defined by H3K27Ac (E).
forming a loop of 295 kb was also present (with coordinates
chr2:145305000–145310000 and chr2:145600000–145605000) in
the same area and formed another small TAD (black arrow,
Fig. 3C). The coordinates for this proximity fall in one intron
of LINC01412 and one intron of TEX41. Both LINC01412 and
TEX41 are very low expressed during neural differentiation of
iPSCs (SupplementaryMaterial, Fig. S5B). H3K27Acmarks are not
present for this 295 kb proximity interaction (data not shown),
whereas they are at the border of the sub-TAD formed by region
A and B (Fig. 3E).
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article/29/15/2535/5867762 by Erasm
us U
niversity R
otterdam
 user on 18 Septem
ber 2020
Human Molecular Genetics, 2020, Vol. 29, No. 15 2541
We therefore focused on the possible REs between region A
and B that are associated with active enhancer marks (Fig. 3E).
CombiningH3K27acmarks and conservation tracks, region B can
be divided in three clusters that possibly represent three novel
candidate enhancers, named Enh1 (chr2:145764483–145765504),
Enh2 (chr2:145769677–145770210) and Enh3 (chr2:145779965–
145780193) (Fig. 3E). Taken together, these data suggest a
time-regulated DNA looping with the aim of bringing the
three enhancers and the ZEB2 promoter in close proximity.
Furthermore, this looping might specifically regulate ZEB2
promoter, and gene transcription, during neural differentiation.
The three novel candidate enhancers act on ZEB2
promoter-based transcription
To functionally investigate the candidate enhancer regions iden-
tified by T2C in iPSCs at D6 of neural differentiation, we cloned
these enhancers in combination with the ZEB2 proximal pro-
moter (chr2:145277927–145278000) in a luciferase-reporter-based
vector and transfected these respective constructs in iPSCs at
the different time points of differentiation (Fig. 4A and B). A
similar basal level of luciferase activation is seen both at D0
(undifferentiated cells) and at D15 (mature NPCs),whereas at D6,
the activation peaks to about 8-fold higher values (Fig. 4B), indi-
cating that the three enhancers, tested away from their normal
location, are bound by one or more transcriptional regulators
specifically produced and active at this cell state.
We also produced combinatorial versions of the enhancers
(Fig. 4A) and transfected the entire panel of enhancers-promoter
combinations to heterologous HEK293T cells (Fig. 4C). The pres-
ence of all three enhancers and the promoter had the strongest
effect on the vector-based luciferase activity. Enh2 in combina-
tion with either Enh1 or Enh3 also induced luciferase activity,
albeit at a lower level. Remarkably, Enh2 by itself was not able
to induce luciferase, indicating a co-operative effect of the three
enhancers with Enh2, which enhances the stimulatory effect of
the other two enhancers.The activity of Enh1 and Enh3 appeared
to be additive, but only if Enh2 was present. We conclude that
the three enhancers co-operate, including in the neural lineage,
in driving ZEB2 expression, and Enh2+Enh3 are required for
sustained ZEB2 transcription.
In-silico motif analysis predicts novel, remote-acting TF
candidates for ZEB2 transcription regulation
Next, we performed an in-silico prediction analysis of TF-binding
elements present in the three enhancers. We used JASPAR
database for human TF motif profiles, considering a >90%
confidence score (48) (http://jaspar.genereg.net). Among the
many and different motifs defined as such, we found collective
enrichment for ETS1, FOXD2, HOXB2, LHX1 and 9, OTX2, SOX10
and 15, and YY1 in the enhancers (Fig. 5A). In particular, ETS1
seems a candidate for binding to Enh1 and Enh2, whereas
Enh3 has just SOX15 and HOXB2 passing the applied 90%
confidence threshold. Figure 5B shows the log2 Fold Change
(log2FC) and Supplementary Material, Figure S6 the normalized
values of the mRNAs for these TFs, as determined via our RNA-
seq. FOXD2 and HOXB2 are the top upregulated genes among
the possible TFs involved, while SOX10 and ETS1 show a very
moderate upregulation (Fig. 5B). The other possible TFs are
overall downregulated during differentiation (Fig. 5A).
To verify that FOXD2 and/or HOXB2 regulate the enhancers’
activity, we transfected NPCs with shRNAs directed against
these two TFs and also for SOX10, for which a crosstalk
with ZEB2 is already known (49–53) (Fig. 5C). The knockdown
(KD) of HOXB2 and SOX10 resulted in increased luciferase
activity, while FOXD2 KD has no significant effect on the
enhancers. Therefore, we propose that upstream HOXB2 and
SOX10 might be necessary for or contributing to transcriptional
repression of ZEB2.
Discussion
Highly dynamic chromatin architecture accompanies stem cell
differentiation, each change being reflected in state/stage-
specific gene-signatures, often of direct relevance to specific
lineage commitment and progression. Many genes involved
in developmental processes that need to be temporally and/or
spatially regulated are located in-cis of long gene deserts, such
as Shh, HoxD and Sox9 (54–56). These gene deserts contain
several REs, either enhancers or silencers, which in a number
of cases have been found to regulate the expression of the
aforementioned gene(s) in a time, cell-type and/or tissue and
location specific manner (54,57,58).
Here, we have started to add ZEB2 as another acknowledged
and developmental/disease relevant locus located downstream
of a 3.3 Mb-long gene desert, with at least in the ZEB2-
proximal 500 kb the identification of three hitherto unknown
enhancers that co-operate in neural differentiation. These
results demonstrate for the first time the value of T2C
for studies of locus-specific transcription in the context of
chromatin conformation and concomitant DNA looping. T2C
has already been used to study global chromatin conformation
and interactome at high-resolution (sub-kbp) and high coverage,
with low sequencing efforts and at affordable cost (42,59–61). In
addition, for ZEB2 itself, functional studies and dynamics in
cell differentiation (including in vertebrate models, but also in
MOWS patients) T2C and hence DNA looping in the ZEB2 locus
can now be added to other types of functional study, including
identification of ZEB2 direct target genes (ChIP-sequencing) and
co-operation with other partners (ZEB2 interactome) (14,16,62–
64). We have previously shown, both in vivo (often in the mouse)
and in vitro, that detectable Zeb2 temporal expression directly
correlates with cell state and behavior (e.g. differentiation,
maturation, migration, epithelial-mesenchymal transition) (23–
26). In addition, by varying the dosage of Zeb2, in (rescued)
knockout mice or via Zeb2 transgene-based (over)production
in wild-type mice, the concept of precise dosage has become
relevant to normal Zeb2 needs or functions, not only in
developmental defect, but also pathology (49,51,65–67). Hence,
studies of mechanisms that regulate ZEB2 mRNA levels, as well
as still needed studies documenting miR-based ZEB2 control
and ZEB2 protein (in)stability, become increasingly relevant
to the field.
In this study, for the first time for the ZEB2 locus, we
report genomic architecture dynamics and identify three novel
enhancers, located about 500 kb upstream of the ZEB2 TSS,
regulating transcription of ZEB2 during neural differentiation.
We initially assess the expression profile of our iPSC line
subjected to neural differentiation, and show that ZEB2 is highly
expressed at D6, corresponding to early NPCs. At this state,
iPSCs have silenced almost completely their pluripotency gene
signature and activated lineage-specific markers. This is in line
with the observation by Chng and co-workers, who studied
neuroectodermal differentiation of human ESCs, where double
inhibition of Activin and BMP signaling results in increase of
ZEB2 mRNA levels up to 6 days of differentiation (68). In mouse
ESCs, the levels of Zeb2mRNA rise at early NPC stage, after which
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Figure 4. The three novel identified enhancers co-operate to drive upregulated activity of theminimal ZEB2 promoter in a cell state/time specific manner. (A) schematic
overview of combinatorial luciferase reporter-based constructs used in this study. (B) Luciferase assay performed in differentiating iPSCs transfected with a luciferase-
based construct containing the three identified enhancers together with the minimal promoter of ZEB2 shows differential luciferase activation according the cell state
A basal level of activation can be observed already at undifferentiated, D0, state. Similar level is also detected at mature NPC state, D15, while the highest expression
is at D6, neural rosette/early NPC state. (C) Luciferase reporter assay of the whole panel of constructs, transiently transfected to heterologous HEK293T cells (see
also the Discussion section). As for NPCs, the three enhancers positively co-operate. MP, minimal promoter of ZEB2. Error bars represent standard deviation of three
independent biological replicates. Statistical significance was calculated with GraphPad Prism using a multiple comparison one-way Anova test. Asterisks represent
P-values: ∗P<0.05; ∗∗P< 0.005; ∗∗∗P< 0.0005; ∗∗∗∗P<0.0001.
they remain high (14). Similar to these ESCs, ZEB2 expression is
still sustained at NPC state as obtained in human iPSCs, and
their NPC state is amenable to T2C analysis.
For our target region of interest, we designed probes to
span roughly 7.4 Mb of chr2, i.e. 143270465–150642631 (hg19
genome reference). These probes cover KYNU, GTDC1, ZEB2,
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Figure 5. HOXB2 and SOX10 can bind the newly identified enhancers to regulate the ZEB2 minimal promoter activity. (A) localization of TF motifs in the sequence of
the three enhancers using a confidence score >90%. (B) Differential expression, during iPSCs neural differentiation, of TFs for which a binding motif has been found
in the enhancer sequences. FOXD2, HOXB2 are upregulated at D6 and D15 and might represent potential candidates able to bind the enhancers. (C) mRNA levels of
HOXB2, SOX10 and FOXD2 after shRNA mediated KD in NPCs. (D) KD of HOXB2 and SOX10, but not of FOXD2, results in increased luciferase activation mediated by the
three novel enhancers and the ZEB2 minimal promoter. Error bars represent standard deviation of three independent biological replicate. Statistical significance was
calculated with GraphPad Prism using a multiple comparison one-way Anova test. Asterisks represent P-values: ∗∗∗P< 0.0005; ∗∗∗∗P< 0.0001.
ACVR2A, ORC4, MBD5, EPC2, KIF5C, LYPD6B, and MMADHC
protein-encoding genes, as well as the two, rather long lncRNA
genes LINC01412 and TEX41, located about 2.6 kb and 160 kb
upstream of the ZEB2 TSS, respectively.Our reconstruction of the
in-cis dynamics of this region of chr2 shows that at iPSC state, the
majority of the detectable proximities are short-range without a
clear TAD structure, indicating a closed conformation in which
the ZEB2 gene is tightly packed and not accessible. As neural
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differentiation proceeds, the chromatin organization reveals
well-defined, distinct TADs, and hence several proximities
are mapped, and ZEB2 is significantly upregulated. The main
sub-TAD involves a loop between the ZEB2 promoter and a
segment of ∼500 kb upstream of its TSS. Based on histone-
3 marks and evolutionary conservation, we identify via T2C
three REs, i.e. Enh1, Enh2 and Enh3, which are active enhancers.
Previous studies, nearly exclusively done using computational
analysis of publicly available databases, have shown the
existence of different enhancers located upstream, downstream
and intergenic/intronic to Zeb2/ZEB2 (30,31). McKinsey and
co-workers propose for their mouse models that two Zeb2
REs are regulated by Dlx1/2, more specifically in gamma-
aminobutyric acid (GABAergic) interneurons of the embryonic
ventral forebrain (30). One of these REs is an enhancer located
about 1.4 Mb upstream of the Zeb2 TSS. Bar-Yaacov and co-
workers identified eight new possible brain-specific human
enhancers, albeit with intergenic or downstream location with
regard to ZEB2 (31). In our T2C approach, we also observe, at
early NPC state, a major chromatin conformational change in
the region containing ZEB2, corroborating the finding by Bar-
Yaacov and colleagues on the regulation of ZEB2 by intragenic
enhancers.
The test of our three novel DNA looping segments for
enhancer activity after transient transfection at each considered
timepoint of differentiation yields that, concomitantly with
the major chromatin remodeling observed at D6, the highest
levels of the luciferase reporter are observed at the same
timepoint/cell state, while a basal, comparable activation is seen
at D0 (undifferentiated state) and D15 (late NPCs). Transfection
of a series of combinatorial enhancers indicates that the three
enhancers work synergistically and that Enh2 and Enh3 alone
do not exert the same effect as Enh1 does, but they seem to act
together. On the basis of the relative roles for Enh1 and Enh3, we
propose that these two enhancers co-operate in a time and/or
tissue specific manner, but only when enhancer 2 is present. Of
the many TFs that can potentially bind these novel enhancers,
HOXB2 and SOX10 are interesting candidates. While SOX10 has
been demonstrated to associate as a protein with ZEB2 (52,53),
nothing is known about a possible interaction between ZEB2
and HOXB2. KD of HOXB2 and SOX10 and assessment of the
luciferase reporter activity in NPCs reveal a role for both TFs
as transcriptional repressor of ZEB2; lower levels of HOXB2 or
SOX10 result in increased expression of the luciferase reporter.
HOXB2 is crucial for proper hindbrain formation and regulation
of oligodendrogenesis in mice, both processes involving the
proper formation of rhombomere 3 (69,70). Hindbrain-specific
enhancers of ZEB have been identified by Bar-Yaacov and
co-workers, suggesting that disruption of these enhancers
might affect ZEB2 expression in the hindbrain and ultimately
proper hindbrain organization (31). In mice, in oligodendrocyte
precursor cell Hoxb2 activates Olig2 transcription, which is
critical as upstream activating TF for Zeb2 (15). Once the
levels of Zeb2, as a result of Zeb2 mRNA upregulation, are
sufficiently high, Zeb2 TF acts in a dual mode: it activates genes
promoting myelinogenesis in the embryonic CNS, whereas it
represses other acknowledged genes that inhibit it (15). We
add yet another potential mechanism underlying precise ZEB2
transcriptional control and propose that HOXB2 may be needed
for or contribute to repression of the newly identified enhancers
and therefore also subsequent precise human ZEB2 activation
and/or upregulation.
In addition to the growing number of control mechanisms
for this critical gene in various stages of development, adult
homeostasis, and differentiation and/ormaturation ofmany cell
types, this will prompt the field to continue to document sim-
ilarities or differences between human and e.g. mouse models,
further assess these controls both in vivo and in vitro, for example
also involving NPCs, and study fine-tuning of ZEB2 mRNA levels
at multiple levels, including locus-specific chromatin conforma-
tional changes. Here we find that the major impact of our newly
identified enhancers is to have ZEB2 expression peak at D6 of
differentiation, whereas at D15 (late NPCs) its steady-state tran-
scription is again lower. The chromatin conformation change we
observed at D6 might be required for a transcriptional boost to
increase ZEB2mRNA levels, such that they become sufficient for
the cells to further proceedwith differentiation.At D15,TFs, such
as HOXB2, which are produced in a time-specific manner and in
our system parallel ZEB2 expression, then intervene to occupy
the enhancers and cause or contribute to negative regulation of
ZEB2. It is also not excluded that ZEB2 and HOXB2 (and SOX10)
co-control each other both by feedback and feedforward regu-
lations, which remains to be investigated in our iPSCs. Further
studies are required to identify other TFs acting as negative
and/or positive regulators of the neural enhancers we have
identified. Interestingly, the expression levels of the other genes
located in our ZEB2 region of interest do not change significantly
during neural differentiation, suggesting that of the many genes
that flank the gene desert, only ZEB2—as the encoded TF is
crucial for proper embryonic development—needs precise and
dynamic regulation.
Of the whole spectrum of mono-allelic mutations described
in MOWS patients, 20% are composed of large gene deletions
(including cytogenetically detectable deletions) that very often
are described to affect a significant part or the entire ZEB2, but
sometimes also neighboring, such as downstream located genes
(22). Such patients have very severe phenotypes that encompass
various, classical MOWS defects, but could very well have other
associated defects due to loss of function of (one or more of)
the other genes. Recently, a patient without a mutation in the
ZEB2 protein-coding exon sequences, but with clear MOWS, was
identified (71). Sequencing identified a 69 kb-long duplication,
located in chr2:145218807–145287401, containing exons 1 and 2,
as well as intron 1 and (part of) intron 2 of ZEB2 (73). In a screen-
ing for copy number variants in genes related to Hirschsprung
Disease, four patients have been described with ZEB2 duplica-
tions of part of exon 1 and all of exon 2, ranging from 1.42 to
1.99 kb (72). Of these patients, three presented mutations in the
RET gene and, in two of these three, also a SOX2 duplication.
In line with our results obtained here, these duplications might
hamper the formation of the TAD structure we identified here
and therefore have an effect on ZEB2 transcription, including
blocking (candidate) TF-binding promoted DNA looping needed
for ZEB2 upregulation.
We also found a sub-TAD formed between the whole ZEB2
gene and the 5′-downstream gene GTDC1 (glycosyltransferase-
like domain-containing 1). In 2017, Aksoy and co-workers
described the sequencing, via DNA paired-end tag, of a patient
affected by global developmental delay, language impairments
and intellectual disability (73). In this patient, they found a de
novo t(2;8) translocation affecting GTDC1 on chromosome 2,
while no annotated gene was involved on chromosome 8. On
chromosome 2, the breakpoint is located in intron 5 of GTDC1.
This translocation might therefore result in an impaired TAD
formation between GTDC1 and ZEB2, which might affect the
expression of both genes.
Our work clearly indicates that T2C-based functional studies
and the identification of novel REs would be beneficial not
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Table 1. Antibodies used in this study
Antibody Commercial source Cat. No. Dilution
OCT4 Abcam Ab19857 1:250
NCAM1/CD56 R&D systems AF2408-SP 1:200
SOX2 Immune systems GT15098 1:400
NESTIN Biolegend 839801 1:200
PAX6 Biolegend 901301 1:200
TUJ1 Biolegend 801202 1:500
ZEB2 SantaCruz sc-48789 1:100
Alexa Fluor Donkey α-Rabbit 488 ThermoFisher Scientific A32790 1:500
Alexa Fluor Donkey α-Goat 594 ThermoFisher Scientific A32758 1:500
Alexa Fluor Goat α-Mouse 488 ThermoFisher Scientific A11001 1:500
Donkey α-Rabbit Cy5 Jackson ImmunoResearch 711-175-152 1:500
only for a better understanding of the connection between RE-
containing developmental and disease loci, such as of ZEB2, and
genome structural organization, but also to clinical geneticists
who will systematically intensify gene desert sequencing on top
of exon-sequencing in diagnostics in the future, and analyze REs
in cell-based functional studies.
Materials and Methods
Induced pluripotent stem cells
The WTC iPSC line was obtained from Dr Bruce Conklin (The
J. David Gladstone Institutes, San Francisco, CA,USA). These cells
were cultured feeder-cells free on 6-well-plates coated with 1%
Geltrex in Essential-8 (E8) Basal Medium (ThermoFisher Scien-
tific), and themediumwas changed daily. For their neural induc-
tion, amodified version of the protocol by Singec and co-workers
was used (74). In brief, 70%-confluent cells were changed to
Neural InductionMedium (NIM): DMEM/F12, supplemented with
20% knock-out serum replacement, 1 mm non-essential amino
acids and 0.1 mm β-EtSH (all from ThermoFisher Scientific),
and a mix of inhibitors (abbreviated as DAP), i.e. 2 μM dorso-
morphin (BMP-inhibitor, Tocris Bioscience), 2 μM A83–01 (TGFβ-
inhibitor, Tocris Bioscience) and 2 μM PNU-74654 (WNT-inhibitor,
Sigma). After 6 days (D6) the medium was replaced with neu-
ral maturation medium: DMEM/F12, 1 mm non-essential amino
acids, 0.1 mm β-EtSH, 1× N2 and 1× B27 without vitamin A
(both ThermoFisher Scientific), and the medium was changed
every day until D15 (NPC-state). A schematic overview of the
culturing conditions and differentiation protocol is depicted in
Figure 1A.
RNA extraction and RNA-sequencing
RNA was extracted using TRIZOL (Sigma) according to the man-
ufacturer’s instruction, and purified using standard extraction
and purification by phenol:chloroform and precipitation by iso-
propanol.
Total RNA for triplicates of three timepoints was checked for
quality on an Agilent Technologies 2100 Bioanalyzer using a RNA
nano assay. All samples had an RIN value >9.10. Triplicate RNA-
Seq libraries were prepared according to the Illumina TruSeq
stranded mRNA protocol (www.illumina.com). Briefly, 200 ng of
total RNA was purified using poly-T oligo-attached magnetic
beads to end upwith poly-A containingmRNA. The poly-A tailed
mRNAwas fragmented, and cDNAwas synthesized using Super-
Script II and random primers in the presence of Actinomycin D.
The cDNA fragments were end repaired, purified with AMPure
XP beads, A-tailed using Klenow exo-enzyme in the presence of
dATP. Paired end adapterswith dual index (Illumina)were ligated
to the A-tailed cDNA fragments and purified using AMPure XP
beads. The resulting adapter-modified cDNA fragments were
enriched by PCR using Phusion polymerase as follows: 30 s at
98◦C, 15 cycles of (10 s at 98◦C, 30 s at 60◦C, 30 s at 72◦C) and
5min at 72◦C.PCRproductswere purified usingAMPureXP beads
and eluted in 30 μL of resuspension buffer. One microliter was
loaded on an Agilent Technologies 2100 Bioanalyzer using a DNA
1000 assay to determine the library concentration and to check
the quality. Cluster generation was performed according to the
Illumina TruSeq SR Rapid Cluster kit v2 (cBot) Reagents Prepa-
ration Guide (www.illumina.com). Briefly, 18 RNA-Seq libraries
were pooled together to get a stock of 10 nM. One microliter
of the 10 nM stock was denatured with NaOH, diluted to 6 pm
and hybridized onto the flowcell. The hybridized products were
sequentially amplified, linearized and end-blocked according
to the Illumina Single Read Multiplex Sequencing user guide.
After hybridization of the sequencing primer, sequencing-by-
synthesis was performed using the HiSeq 2500with a single read
50-cycle protocol followed by dual index sequencing.
Illumina reads were mapped against the GRCh38 human
reference using HiSat2 (75). Gene expression values were called
using htseq-count (version 0.11.2) and Ensemble release 96 and
transcript annotation (76). Sample QC and differential expres-
sion analysis have been performed in R environment for statis-
tical computing (version 3.6.2, https://www.R-project.org/), using
DESeq2 (version 1.20.0;) with the ashr log fold shrinkagemethod-
ology (http://bioconductor.org/packages/release/bioc/html/DESe
q2.html) and tidyverse (version 1.3.0; https://github.com/tidyve
rse/tidyverse) (77–79).
Indirect immunofluorescence
hiPCs were plated on Geltrex
®
coated chamber slides. When
confluent, the cells were differentiated as described before on
the slides and harvested on the selected time points (D0, D6 and
D15). The cells were washed three times with PBS (Sigma) and
fixed for 15min at room temperature (RT)with 4%paraformalde-
hyde (PFA) and washed again thrice 5 min with PBS. The cells
were then permeabilized with 100% ice-cold methanol at −20◦C
for 10 min, washed with PBS thrice for 5 min and then blocked
for 1 h at RT in blocking buffer (5% normal goat or donkey serum
(Jackson Immunoresearch), 0.3% Triton-X in PBS). Cells were
incubated overnight (O/N) at 4◦C with the primary antibodies
(Table 1) in antibody dilution buffer (1% BSA, 0.3% Triton-X in
PBS) in a humidity chamber. The next day, the cells were washed
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Table 2. shRNA sequences used in KD experiments
shRNA Target sequence Oligonucleotide sequence
shRNA HOXB2 #1 CCGCCAAGAAACCCAGCCAAT CCGGCCGCCAAGAAACCCAGCCAATCTCGAGATTGGCTGGGTTTCTTGGCGGTTTTT
shRNA HOXB2 #2 CGGCCTTTAGCCGTTCGCTTA CCGGCGGCCTTTAGCCGTTCGCTTACTCGAGTAAGCGAACGGCTAAAGGCCGTTTTT
shRNA HOXB2 #3 CTTGGATGAAAGAGAAGAAAT CCGGCTTGGATGAAAGAGAAGAAATCTCGAGATTTCTTCTCTTTCATCCAAGTTTTT
shRNA SOX10 #1 CCTCATTCTTTGTCTGAGAAA CCGGCCTCATTCTTTGTCTGAGAAACTCGAGTTTCTCAGACAAAGAATGAGGTTTTT
shRNA SOX10 #2 GCAGCCAGTATATACGACACT CCGGGCAGCCAGTATATACGACACTCTCGAGAGTGTCGTATATACTGGCTGCTTTTT
shRNA SOX10 #3 GCTGCTGAACGAAAGTGACAA CCGGGCTGCTGAACGAAAGTGACAACTCGAGTTGTCACTTTCGTTCAGCAGCTTTTT
shRNA FOXD2 #1 CTTCTCTATAGACCACATCAT CCGGCTTCTCTATAGACCACATCATCTCGAGATGATGTGGTCTATAGAGAAGTTTTT
shRNA FOXD2 #2 GCCTTCCTTCTCTATAGACCA CCGGGCCTTCCTTCTCTATAGACCACTCGAGTGGTCTATAGAGAAGGAAGGCTTTTT
shRNA FOXD2 #3 CGAGGCAGACTTAGCCGAGGA CCGGCGAGGCAGACTTAGCCGAGGACTCGAGTCCTCGGCTAAGTCTGCCTCGTTTTT
scrambled control CAACAAGATGAAGAGCACCAA CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT
Table 3. Primer sequences used for RT-qPCR analyses
Primer Oligonucleotide sequence
ACTIN_Fwd TCCCTGGAGAAGAGCTACGA
ACTIN_Rev AGCACTGTGTTGGCGTACAG
HOXB2_Fwd GAATTTGAGAGGGAGATTGGGT
HOXB2_Rev GGGAAGGTTTGCTCGAAAGG
SOX10_Fwd ACAAGAAAGACCACCCGGAC
SOX10_Rev AAGTGGGCGCTCTTGTAGTG
FOXD2_Fwd TGCGCCAAAGCCTTCTAC
FOXD2_Rev TGGCCCATGATGTGGTCTAT
three times with PBS for 5 min and incubated with the corre-
sponding fluorescent secondary antibody in antibody dilution
buffer for 1.5 h at RT in the dark. After washing the cells three
times for 5 min with PBS, the cells were mounted with Mowiol
(Sigma) containing DAPI (1:1000, Sigma-Aldrich) and dried O/N
in the dark. Images were acquired with a Leica SP5 confocal
microscope.
Targeted chromatin capture
The T2C protocol was adapted fromKolovos and co-workers (80).
Cells were collected at D0, D6 and D15 of neural differentiation,
using Accutase
®
(ThermoFisher Scientific) and passed through
a 40-μm cell strainer (BD Falcon). 2.5x106 cells were used for
each time point; the cells were cross-linked using 1% formalde-
hyde at room temperature (RT, 24◦C) for 10 min and quenched
with 0.125 M glycine. Subsequently, cells were lysed using cold
lysis buffer containing 10 mm Tris-HCl pH 8.0, 10 mm NaCl,
0.5%NP-40 and complete protease inhibitors (Roche). Chromatin
was digested with the ApoI restriction enzyme (New Englad
Biolabs) (400 U/sample) overnight in a thermomixer (VWR) at
37◦C at 900 rpm. The digested products were purified via Phe-
nol:Chloroform. The diluted DNA fragments were ligated with
T4 DNA Ligase High Concentration (100 U/sample; ThermoFisher
Scientific) overnight at 16◦C, and then 30 μL of 10 mg Proteinase
K/ml (300 μg) were added and incubated at 65◦C for 4 h, followed
by 30 μL of 10 mg RNAse A/mL (300 μg) for 1 h at 37◦C, before
proceeding to further purification with Phenol:Chloroform. In
total, 6 μg of the resulting chromatin were then linearized using
the frequent 4 bp-cutting enzyme DpnII (New England Biolabs)
(1 U/μg of DNA) overnight at 37◦C, while shaking in a ther-
momixer at 400 rpm. The day after, the material was precipi-
tated by sodiumacetate/ethanol before proceeding to T2C library
preparation.
For each sample, a T2C Library was prepared using 250 ng of
linearized chromatin. The samples were re-buffered to 10 mm
Tris-HCl, pH 8 by a standard AMPure XP (Agencourt) bead
clean-up procedure. The chromatin was sheared to 300–400-
bp fragments by a S220 Covaris (Covaris Inc.). Concentration
was determined by Quant-it high sensitivity (ThermoFisher
Scientific). For each sample 100 ng of sheared chromatin was
end-repaired and A-tailed using the Kapa hyper prep kit (Roche)
according to the manufacturer’s instructions. SeqCap library
adaptors were ligated followed by AMPure bead clean-up. The
pre-capture library was amplified by PCR using KAPA HiFi
hotstart readymix for 9 cycles. The amplified pre-capture library
was purified by bead clean-up and quantified by Bioanalyzer
DNA1000 assay (Agilent) according to the manufacturer’s
instructions. A ZEB2 hg19-based design was ordered at Nim-
bleGen (Roche) with baits located between 143270465 and
150642631 of chromosome 2.A hybridizationmixture per sample
was preparedwith 2 μg pre-capture library, 1mmHE-index-oligo,
1 mm HE universal oligo, COT Human DNA, AMPure XP reagent
and added to 4.5 μL of pre-ordered baits and subsequently
hybridized for 16 h at 47◦C. Post hybridization, the samples
were washed according to the instructions in the Nimblegen
SeqcapEZ Hypercap workflow (Roche), the chromatin captured
using capture beads. The captured library was amplified by PCR
using Kapa HiFi mix and purified by AMPure XP beads. The
captured librarywas quantified byNanodrop spectrophotometer
and the quality was assessed using a Bioanalyzer DNA1000
assay. Finally, the captured T2C libraries were denatured and
sequenced on an Illumina HiSeq2500 sequencer as described for
RNA-seq but with a custom recipe of 6 dark cycles, followed by
paired end 101 sequencing with single index using the rapid v2
chemistry according to manufacturer’s instructions (Illumina).
T2C analysis was performed as described in Kolovos and
co-workers (80). In short, reads were aligned to the human
GRCh37 reference genome with the BWA aligner and the BWA-
backtrack method. Alignments were subsequently annotated
with the restriction fragments in which they were located. The
proximity matrix was then constructed from the mapped pri-
mary alignments with their mapped primary mates. Further
analyses and filtering based on the proximity matrix was per-
formed in the R environment for statistical computing.
Cloning and luciferase assay and shRNA experiments
Clonable DNA fragments encoding the candidate putative
enhancers and the minimal promoter of human ZEB2 were
produced as a single gBlock (IDT), which was then inserted
in the luciferase-based pGL4.10 vector (Promega). HEK293T
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cells, cultured in high glucose (4.5 g/L) DMEM supplemented
with 10% FBS, were co-transfected with 1.5 μg of luciferase
construct, containing different combinations of enhancers with
the ZEB2 minimal promoter, and 50 ng Renilla-based vector,
using Lipofectamine-2000 in a 1:1.5 ratio. Empty pGL4.10 was
used as negative control. NPCs were transfected with Amaxa
Nucleofector II, using the Kit V (Lonza) and transfection program
A-33. 4.5 μg of luciferase-construct were transfected with 50 ng
of Renilla-encoding vector to 400000 cells grown in a 12-
well plate. After 24 h the cells were lysed in 1x Passive Lysis
Buffer (PLB) (Promega). Luciferase and Renilla activity were
measured in a Varioskan Lux Microplate reader (ThermoFisher
Scientific) using the Dual-Luciferase Reporter Assay System
(Promega). Enhancer activity was calculated as the fold-change
of Luciferase normalized to Renilla activity. Each transfection
was performed three times, and of each transfection, three
technical replicates were measured.
For the KD experiments, shRNAs for HOXB2, SOX10 or FOXD2
were transfected/co-transfected with the luciferase-constructs.
Table 2 lists the shRNA sequences used for the KD. Medium was
refreshed 24 h after transfection, and the cells were harvested
48 h after the transfection. To address the KD efficiency, RNA
was isolated, and cDNA was synthesized as described above,
and expression levels were tested by real-time quantitative PCR
(RT-qPCR). RT-qPCRwas performed using SybrGreen dye (BioRad)
on a CFX96 T1000 thermal cycler. All data shown are averages
of three independent biological replicates and three technical
replicates, normalized to ß-ACTIN. Primers are listed in Table 3.
Luciferase activity after KD was performed as described above.
Data Availability
T2C data are available under the GEO accession number
GSE147000.
Supplementary Material
Supplementary Material is available at HMG online.
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